Morbidity of pandemic H1N1 influenza in children with cancer

Caselli, Desireé; Carraro, Francesca; Castagnola, Elio; Ziino, Ottavio; Frenos, Stefano; Milano, Giuseppe Maria; Livadiotti, Susanna; Cesaro, Simone; Marra, N; Zanazzo, Giulio Andrea; Meazza, Cristina; Cellini, Monica

doi:10.1002/pbc.22619

Cited by 37 publications

(39 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…3 Two small studies of children with malignancies infected with the A/H1N1 pandemic strain also suggest relatively mild disease. 18,19 Lymphopenia has been identified as a risk factor for LRT disease, both for influenza and for infections with other respiratory viruses. 5 Although we found that neutropenia was a significant risk factor for death, this was not the case for pneumonia or for mechanical ventilation.…”

Section: Resultsmentioning

confidence: 99%

Outcome of pandemic H1N1 infections in hematopoietic stem cell transplant recipients

Cámara²,

et al. 2011

View full text Add to dashboard Cite

During 2009, a new strain of A/H1N1 influenza appeared and became pandemic. A prospective study was performed to collect data regarding risk factors and outcome of A/H1N1 in hematopoietic stem cell transplant recipients. Only verified pandemic A/H1N1 influenza strains were included: 286 patients were reported, 222 allogeneic and 64 autologous recipients. The median age was 38.3 years and the median time from transplant was 19.4 months. Oseltamivir was administered to 267 patients and 15 patients received zanamivir. One hundred and twenty-five patients (43.7%) were hospitalized. Ninety-three patients (32.5%) developed lower respiratory tract disease. In multivariate analysis, risk factors were age (OR 1.025; 1.01-1.04; P=0.002) and lymphopenia (OR 2.49; P<0.001). Thirty-three patients (11.5%) required mechanical ventilation. Eighteen patients (6.3%) died from A/H1N1 infection or its complications. Neutropenia (P=0.03) and patient age (P=0.04) were significant risk factors for death. The 2009 A/H1N1 influenza pandemic caused severe complications in stem cell transplant recipients.Key words: H1N1, influenza, pandemic, HSCT. Citation: Ljungman P, de la Camara R, Perez-Bercoff L, Abecasis M, Nieto Campuzano JB, Cannata-Ortiz MJ, Cordonnier C, Einsele H, Gonzalez-Vicent M, Espigado I, Halter J, Martino R, Mohty B, Sucak G, Ullmann AJ, Vázquez L, Ward KN, and Engelhard D for the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation (EBMT) and the Infectious Complications Subcommittee of the Spanish Group of Haematopoietic Stem-cell Transplantation (GETH).Outcome of pandemic H1N1 infections in hematopoietic stem cell transplant recipients. Haematologica 2011;96(8):1231-1235. doi:10.3324/haematol.2011 This is an open-access paper. ABSTRACT Outcome of pandemic H1N1 infections in hematopoietic stem cell transplant recipients Design and MethodsData was collected through two prospective surveys; one from the European Group for Blood and Marrow Transplantation (EBMT) and the other from the Infectious Complications Subcommittee of the Spanish Group of Haematopoietic Stem Cell Transplantation (GETH). All centers belonging to the two organizations were invited to take part. Data were collected from July 2009 through May 2010. While not identical, both surveys collected information through standardized case-collection forms regarding patients' characteristics and their treatment, factors determining their immunosuppressed state, characteristics of the influenza infection, complications, vaccination status, antiviral therapy and outcome. All patients had given their consent to the data collection. Institutional review board approval was sought as required locally at participating centers. Only patients with molecular proof of pandemic influenza A/H1N1 were included. Oseltamivir resistance was assessed when feasible and as clinically indicated by nucleic acid sequencing of the A/H1N1 neuraminidase gene.Lower respiratory tract (LRT) disease was defined as presence of pulmonary infiltrates and...

show abstract

Section: Resultsmentioning

confidence: 99%

Outcome of pandemic H1N1 infections in hematopoietic stem cell transplant recipients

Cámara²,

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Pathogens as Pseudomonas spp., Enterobacter spp., Streptococcus spp. and coagulase-negative staphylococci [6,8] have been described. Secondary bacterial infections may also occur as clinical infections, such as pneumonia or otitis media [10].…”

Section: Complicationsmentioning

confidence: 99%

“…In one population of children with 2009 pandemic influenza infection, 55% of the children experienced treatment delays averaging 3 weeks; the longest delay in this group was 43 days. Others have also reported average treatment interruptions of 3 weeks or more [6,8]. The impact of treatment interruptions due to influenza specifically is unknown; however, emerging evidence suggests that relapse rates are higher among children with acute…”

Section: Impact On Chemotherapymentioning

confidence: 99%

“…Active surveillance for influenza-like illness conducted on pediatric and adult oncology units during the 2009 influenza pandemic revealed that 20% of patients hospitalized with fever were infected with influenza [5]. Other studies have suggested that as many as two-thirds of pediatric oncology patients who were diagnosed with influenza during that 2009 pandemic required hospitalization [6]; complications occurred in 10%-20% of those hospitalized [7][8][9][10]. This review includes recent information on the risks associated with specific pediatric oncology patient populations, preventive strategies, and management options.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Protecting Pediatric Oncology Patients From Influenza

et al. 2013

View full text Add to dashboard Cite

Influenza is a common respiratory pathogen. Its severity can be unpredictable, but people with chronic illness are at increased risk of severe infection, complications, and death from influenza. This review examines evidence to support various strategies to protect pediatric oncology patients from influenza-related morbidity. Influenza vaccination should be considered standard. Additional evidence-supported measures include antiviral treatment, antiviral prophylaxis, cohorting of patients, and hospital infection control measures. Data from other high-risk populations support the vaccination of family members, double-dose or high-dose vaccination, and the use of barrier methods. These measures have the potential to optimize patient outcomes because there will be fewer treatment interruptions for acute illness. These strategies can also protect patients from prolonged hospitalizations and morbidity related to influenza. The Oncologist 2013;18:204 -211 Implications for Practice: Pediatric oncology patients can have very severe infections with the influenza virus. Their vulnerability is due to chronic illness and immune suppression. Simple strategies, such as ensuring vaccination, infection control measures, and education regarding personal protection can protect this population that is susceptible to severe influenza.

show abstract

“…И уже не остается сомнений, что это совсем не «безобидное» заболевание. В результате сдвига микробио-ценоза влагалищной среды женщины становятся более уязвимыми перед агрессией различных микроорганиз-мов, таких как дрожжеподобные грибы рода Candida [5].…”

unclassified

Possibilities for combined therapy in patients with bacterial vaginosis concurrent with vulvovaginal candidiasis

Savelyeva¹,

Polyanskaya²

2016

Ross. vestn. akush.-ginekol.

View full text Add to dashboard Cite

Morbidity of pandemic H1N1 influenza in children with cancer

Abstract: H1N1 infection in children with cancer was not reported as the cause of death in any case but resulted in reduced intensity of anti-cancer therapy.

Cited by 37 publications

References 3 publications

Outcome of pandemic H1N1 infections in hematopoietic stem cell transplant recipients

Outcome of pandemic H1N1 infections in hematopoietic stem cell transplant recipients

Protecting Pediatric Oncology Patients From Influenza

Possibilities for combined therapy in patients with bacterial vaginosis concurrent with vulvovaginal candidiasis

Contact Info

Product

Resources

About